These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18695695)

  • 21. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
    Steinberg BA; Cannon CP
    Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rimonabant. Risk of depression has not been finally clarified].
    Kreutzkamp B
    Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
    [No Abstract]   [Full Text] [Related]  

  • 23. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of rimonabant on weight and cardiometabolic risk factors.
    Gadde KM
    JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103
    [No Abstract]   [Full Text] [Related]  

  • 25. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
    Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
    Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
    Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
    Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
    Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.
    Aronne LJ; Isoldi KK
    Am J Cardiol; 2007 Dec; 100(12A):18P-26P. PubMed ID: 18154742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
    Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
    Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
    [No Abstract]   [Full Text] [Related]  

  • 33. [Nutrition-obesity. Rimonabant and cardiovascular risk factors].
    Vincent M; Golay A
    Rev Med Suisse; 2009 Jan; 5(185):49-52. PubMed ID: 19216325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 35. Endocannabinoid system and cardiometabolic risk.
    Saavedra LE
    Clin Pharmacol Ther; 2007 Nov; 82(5):591-4. PubMed ID: 17898706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depression and weight loss: opposite outcome for surgery and rimonabant?
    Chaput JP; Tremblay A
    Obes Rev; 2008 Sep; 9(5):504-7. PubMed ID: 18643944
    [No Abstract]   [Full Text] [Related]  

  • 37. CB1 antagonists for obesity--what lessons have we learned from rimonabant?
    Di Marzo V; Després JP
    Nat Rev Endocrinol; 2009 Nov; 5(11):633-8. PubMed ID: 19844251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabinoids and cardiovascular disease: the outlook for clinical treatments.
    Ashton JC; Smith PF
    Curr Vasc Pharmacol; 2007 Jul; 5(3):175-85. PubMed ID: 17627561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.
    Bifulco M; Pisanti S
    Nat Rev Drug Discov; 2009 Jul; 8(7):594. PubMed ID: 19568284
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacotherapy for obesity--promise and uncertainty.
    Yanovski SZ
    N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.